About Us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

About
us

At Cytovation, we are on a mission to make immunotherapy effective across a wide range of cancer types.

Who We Are

Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering highly stable synthetic peptides with unique, antitumoral properties.

CY-101, the company’s lead candidate is being developed as a novel, first-in-class immunotherapy, that drives a tumor-specific immune response with a dual mode of action.

Management

CEO

Lars Prestegarden

COO/CFO

Federico Grego

Regulatory and CMC Coordinator

Diane Cowie

Clinical Project Manager

Jeanette Kamman

Lead CRA

Sandra Jansen

Deputy CFO

Vetle Veiteberg

Board

Chairman

Stein-Christian Mohn

Board Member

Ellen Lubman

Board Member

Olav Hellebø

Board Member

Øyvind Kongstun Arnesen

Board Member

Hilde Hukkelberg

Advisors

Rolf Bjerkvig

Ole-Erik Iversen

Bo Jesper Hansen

Raj Airey